JPH0365497B2 - - Google Patents
Info
- Publication number
- JPH0365497B2 JPH0365497B2 JP58061010A JP6101083A JPH0365497B2 JP H0365497 B2 JPH0365497 B2 JP H0365497B2 JP 58061010 A JP58061010 A JP 58061010A JP 6101083 A JP6101083 A JP 6101083A JP H0365497 B2 JPH0365497 B2 JP H0365497B2
- Authority
- JP
- Japan
- Prior art keywords
- blood
- tube body
- plasma
- tube
- components
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004369 blood Anatomy 0.000 claims description 79
- 239000008280 blood Substances 0.000 claims description 78
- 210000000601 blood cell Anatomy 0.000 claims description 32
- 239000003795 chemical substances by application Substances 0.000 claims description 29
- 239000003146 anticoagulant agent Substances 0.000 claims description 23
- 229940127219 anticoagulant drug Drugs 0.000 claims description 23
- 238000000926 separation method Methods 0.000 claims description 17
- 230000005484 gravity Effects 0.000 claims description 8
- 230000009974 thixotropic effect Effects 0.000 claims description 4
- 238000012360 testing method Methods 0.000 description 15
- 230000015271 coagulation Effects 0.000 description 12
- 238000005345 coagulation Methods 0.000 description 12
- 230000023555 blood coagulation Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 206010053567 Coagulopathies Diseases 0.000 description 5
- 208000015294 blood coagulation disease Diseases 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000009852 coagulant defect Effects 0.000 description 5
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 5
- 239000001509 sodium citrate Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000691 measurement method Methods 0.000 description 3
- ZNCPFRVNHGOPAG-UHFFFAOYSA-L sodium oxalate Chemical compound [Na+].[Na+].[O-]C(=O)C([O-])=O ZNCPFRVNHGOPAG-UHFFFAOYSA-L 0.000 description 3
- 229940039790 sodium oxalate Drugs 0.000 description 3
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- 108010000499 Thromboplastin Proteins 0.000 description 2
- 102000002262 Thromboplastin Human genes 0.000 description 2
- 230000002429 anti-coagulating effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/491—Blood by separating the blood components
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Ecology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Centrifugal Separators (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
【発明の詳細な説明】
発明の背景
技術分野
本発明は、臨床検査として、血液の止血機構に
関与する凝血因子の異常を検査可能とする試料の
採取に用いられる血液分離管に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a blood separation tube used for collecting a sample as a clinical test to enable testing for abnormalities in coagulation factors involved in the hemostasis mechanism of blood.
従来技術
上記血液凝固系検査法として、血漿カルシウム
再加時間測定法、血漿プロトロンビン値測定法、
部分トロンボプラスチン時間測定法、トロンボプ
ラスチン形成試験等が知られている。Prior art The above blood coagulation system testing methods include plasma calcium reaccumulation time measurement method, plasma prothrombin level measurement method,
Partial thromboplastin time measurement method, thromboplastin formation test, etc. are known.
従来の上記各血液凝固系検査法にあつては、血
液を採取可能とする有底管本体と、該管本体内に
装填される3.8％クエン酸ナトリウム溶液、3.13
％クエン酸ナトリウム溶液、0.1Mシユウ酸ナト
リウム溶液等の抗凝血剤と、該管本体口部に嵌着
せしめられる栓体とを有してなる血液凝固系検査
法採血管が用いられている。 For each of the above-mentioned conventional blood coagulation system testing methods, a bottomed tube body from which blood can be collected, a 3.8% sodium citrate solution loaded in the tube body, and 3.13
% sodium citrate solution, 0.1M sodium oxalate solution, etc., and a blood coagulation system test method blood collection tube comprising an anticoagulant such as a 0.1M sodium oxalate solution and a stopper fitted to the mouth of the tube body. .
すなわち、上記従来の各血液凝固系検査法にお
いては、上記採血管に血液を採取した後、該採血
管を遠心分離機にかけて、血漿成分と血球成分と
を分離し、分離した血漿成分をピペツト等で他の
容器に移しかえる操作を必要とし、その後、該血
漿成分に各検査法に応じて定められている他の試
薬を加え、該血漿の凝固時間を測定することによ
り、被検血液の各種凝血障害の診断を可能として
いる。 That is, in each of the conventional blood coagulation testing methods described above, after blood is collected into the blood collection tube, the blood collection tube is centrifuged to separate plasma components and blood cell components, and the separated plasma components are pipetted, etc. After that, other reagents specified according to each test method are added to the plasma components, and the coagulation time of the plasma is measured. This makes it possible to diagnose coagulation disorders.
しかしながら、上記従来の採血管を用いる場合
には、遠心分離された血漿成分を他の容器に移し
かえる操作を必要とするとともに、その移しかえ
操作においてピペツト等の器具を血漿成分中に挿
入する際に血漿成分や浮遊した血球成分によつて
汚染される虞れがある。このように血漿成分が血
球成分によつて汚染される場合には、該血漿の透
明度が低下して、該血漿に一瞬にして生ずる凝固
完了の終結点を速やかに判定することができない
等凝固時間の正しい測定が困難となり、被検血液
の凝血障害を適確に診断することが困難となる。 However, when using the above conventional blood collection tube, it is necessary to transfer the centrifuged plasma component to another container, and during the transfer operation, it is necessary to insert an instrument such as a pipette into the plasma component. There is a risk of contamination by plasma components and floating blood cell components. When plasma components are contaminated with blood cell components in this way, the transparency of the plasma decreases and the isocoagulation time, which occurs instantaneously in the plasma, makes it impossible to quickly determine the end point of completion of coagulation. Therefore, it becomes difficult to accurately measure coagulation disorders in the blood to be tested.
また、抗凝血剤の作用が不充分である場合に
は、血漿中の繊維素に血球成分がからみついて凝
血し、検査結果を不正確にすることがあつた。 Furthermore, if the anticoagulant's effect was insufficient, blood cell components could become entangled with fibrin in the plasma, resulting in blood clots, making test results inaccurate.
なお、特開昭57−37259号公報には、容器内に、
血清または血漿成分と血餅または血球成分との中
間比重を有する分離剤を具備し、ストツパー（栓
体）に抗凝固剤の層を具備する血液収集装置が提
案されている。 In addition, in Japanese Patent Application Laid-Open No. 57-37259, there is a
A blood collection device has been proposed which includes a separating agent having a specific gravity intermediate between that of serum or plasma components and blood clots or blood cell components, and which includes a stopper with a layer of anticoagulant.
また、特開昭58−38536号公報には、容器内に、
血清または血漿成分と血餅または血球成分との中
間比重を有する分離剤と、種々の試薬を備えた支
持材料とを具備する血液収集装置が提案されてい
る。 In addition, in Japanese Patent Application Laid-Open No. 58-38536, in the container,
Blood collection devices have been proposed that include a separating agent with a specific gravity intermediate between serum or plasma components and clot or blood cell components, and a support material with various reagents.
しかしながら、特開昭57−37259号公報は、ス
トツパー（栓体）の表面に抗凝固剤の層を設ける
ことで血球の付着を抑制するものに過ぎず、採取
した血液に抗凝固剤を溶解させ抗凝固作用を生じ
させるものではない。 However, JP-A No. 57-37259 merely suppresses the adhesion of blood cells by providing a layer of anticoagulant on the surface of the stopper; instead, the anticoagulant is dissolved in the collected blood. It does not cause anticoagulant effects.
また、特開昭58−38536号公報は、支持材料上
の試薬として抗凝固剤を含むものではあるが、分
離剤が血漿成分と血球成分とを分離する作用を、
支持材料が妨害し、抗凝固剤により凝結作用を抑
制された血漿成分を血球成分によつて汚染される
ことのない状態で遠心分離することに困難があ
る。 Furthermore, although JP-A-58-38536 contains an anticoagulant as a reagent on the support material,
There are difficulties in centrifuging the plasma component, which is hindered by the support material and whose clotting effect is inhibited by the anticoagulant, without being contaminated by blood cell components.
発明の目的
本発明は、採取した血液に、所定の凝固系検査
用試薬を混和させるとともに、他の容器に移しか
えることなく、血球成分によつて汚染されること
のない血漿成分を試料として提供可能とし、被検
血液の凝血障害を容易にかつ適確に診断可能とす
る血液凝固系検査用採血管を提供することを目的
とする。 Purpose of the Invention The present invention provides plasma components as a sample that are not contaminated by blood cell components by mixing collected blood with a prescribed coagulation system test reagent and transferring it to another container. It is an object of the present invention to provide a blood collection tube for blood coagulation system testing, which enables easy and accurate diagnosis of coagulation disorders in sample blood.
上記目的を達成するために、本発明に係る血液
分離管は、管体の一端が開口し、他端が閉塞した
有底採血管本体と、該管本体の開口部を密封する
穿刺可能な栓体と、該管本体内に収容され、分離
すべき血漿成分と血球成分の中間比重を有するチ
キソトロピー性分離剤と、該管本体の内部であつ
て該栓体と接する空間内に血液との接触により血
液中に分散可能に分離剤上部に位置する抗凝血剤
溶液とを具備し、かつ凝固が防止された血液が遠
心分離された後、該血液から血球成分が隔離され
るようにしたものである。 In order to achieve the above object, the blood separation tube according to the present invention includes a bottomed blood collection tube body with one end open and the other end closed, and a punctureable stopper that seals the opening of the tube body. a thixotropic separation agent housed in the tube body and having a specific gravity intermediate between the plasma component and blood cell component to be separated, and contact with blood in a space inside the tube body and in contact with the stopper; and an anticoagulant solution located above the separating agent so that it can be dispersed in the blood, and after the blood whose coagulation has been prevented is centrifuged, blood cell components are isolated from the blood. It is.
また、本発明は、前記血液分離管内部が所定の
採血量に対応する減圧状態に保持されてなるよう
にしたものである。 Further, in the present invention, the inside of the blood separation tube is maintained at a reduced pressure state corresponding to a predetermined amount of blood to be collected.
上記本発明によれば、以下の作用効果がある。 According to the present invention, there are the following effects.
本発明は、抗凝血剤溶液を分離剤上部に位置さ
せた。 The present invention places the anticoagulant solution on top of the separation agent.
すなわち、抗凝血剤が液状でありかつ分離剤上
部に位置するので、採取した血液は素早く抗凝血
剤と混合し、さらに遠心分離する際に流動性を呈
した分離剤の動きを妨げるものがない。よつて、
血漿成分と血球成分の境に移動し遠心力の停止に
伴い２成分を相互に隔絶する壁を形成することが
できる。従つて、抗凝血剤により凝血作用を抑制
された血漿成分は血球成分と隔離された状態を維
持することができる。 In other words, since the anticoagulant is in a liquid state and is located above the separating agent, the collected blood quickly mixes with the anticoagulant and further prevents the movement of the fluid separating agent during centrifugation. There is no. Afterwards,
It can move to the boundary between plasma components and blood cell components and form a wall that separates the two components from each other when the centrifugal force stops. Therefore, plasma components whose coagulation effect is suppressed by the anticoagulant can be maintained in a state separated from blood cell components.
発明の具体的説明
第１図は本発明の一実施例に係る採血管１０を
示す断面図である。採血管１０は、血液を採取可
能とする有底管本体１１と、管本体１１の内部に
装填される溶液状の抗凝血剤１２と、管本体１１
の口部１３に嵌着せしめられる栓体１４とを有し
ている。更に、採血管１０の管本体１１には、採
取され遠心分離によつて分離された血漿成分と血
球成分とを分画するゲル状の分離剤１５が装填さ
れている。なお分離剤１５は、最初は管本体１１
の底部側に位置しており、抗凝血剤１２は、分離
剤１５の上部に位置している。 DETAILED DESCRIPTION OF THE INVENTION FIG. 1 is a sectional view showing a blood collection tube 10 according to an embodiment of the present invention. The blood collection tube 10 includes a bottomed tube body 11 that allows blood to be collected, a solution anticoagulant 12 loaded inside the tube body 11, and a tube body 11.
It has a plug body 14 that is fitted into the mouth part 13 of. Further, the tube body 11 of the blood collection tube 10 is loaded with a gel-like separating agent 15 that separates plasma components and blood cell components that have been collected and separated by centrifugation. Note that the separating agent 15 is initially applied to the tube body 11.
The anticoagulant 12 is located at the top of the separating agent 15.
管本体１１は透明のガラス、プラスチツク等か
らなり、栓体１４はブチルゴム等からなる。この
栓体１４は、管本体１１の内部を密封し、管本体
１１の内部に所定の採血量に対応する所定の陰圧
状態を形成保持可能とするとともに、第２図に示
すように、採血ホルダー１６に設けられている採
血針１７の刺通を可能としている。 The tube body 11 is made of transparent glass, plastic, etc., and the plug body 14 is made of butyl rubber, etc. This plug body 14 seals the inside of the tube body 11, and makes it possible to form and maintain a predetermined negative pressure state corresponding to a predetermined amount of blood to be collected inside the tube body 11, and as shown in FIG. This allows the blood collection needle 17 provided in the holder 16 to penetrate.
抗凝血剤１２としては、試みられる各血液凝固
系検査法に応じて定められている薬剤、例えば、
3.8％クエン酸ナトリウム溶液、3.13％クエン酸
ナトリウム溶液、0.1Mシユウ酸ナトリウム溶液
等が用いられる。なお、クエン酸ナトリウム溶液
は、血液９容に対して１容とされている。 The anticoagulant 12 may be a drug determined according to each blood coagulation test method to be attempted, such as:
A 3.8% sodium citrate solution, a 3.13% sodium citrate solution, a 0.1M sodium oxalate solution, etc. are used. Note that the sodium citrate solution is 1 volume per 9 volumes of blood.
分離剤１５は、前述のように、最初は管本体１
１の底部側に位置しており、実質的に疎水性かつ
揺変性（チキソトロピー性）であるとともに、血
液に対して実質的に不活性で、かつ分離される血
漿成分と血球成分の中間の比重を有している。し
たがつて、分離剤１５は血液を採取した採血管１
０が遠心分離機にかけられると、流動性を呈して
上記２成分の境に移動し、遠心力の停止に伴い上
記２成分を相互に隔絶する半固体状すなわち非流
動的な状態の壁を形成する。 As mentioned above, the separating agent 15 is initially applied to the tube body 1.
1, is substantially hydrophobic and thixotropic, is substantially inert to blood, and has a specific gravity intermediate between the plasma component and blood cell component to be separated. have. Therefore, the separating agent 15 is attached to the blood collection tube 1 from which the blood was collected.
When 0 is centrifuged, it exhibits fluidity and moves to the boundary between the two components, and when the centrifugal force stops, it forms a semi-solid or non-fluid wall that separates the two components from each other. do.
ここで、上記分離剤１５としては、公知のもの
が使用可能で、例えば、粘度10000〜80000cp（25
℃）のα−オレフイン・マレイン酸ジエステル共
重合体を主成分とするものやシリコーンを主成分
とし、これに粘度・比重調整剤を添加してなり、
比重1.035〜1.055であるもの等が用いられる。 Here, as the separating agent 15, a known one can be used, for example, a viscosity of 10,000 to 80,000 cp (25
℃) whose main component is α-olefin/maleic acid diester copolymer or silicone, with the addition of a viscosity/specific gravity modifier,
Those having a specific gravity of 1.035 to 1.055 are used.
発明の具体的作用
まず、採血針１７の外端１７Ａを患者の静脈に
穿刺するとともに、採血針の内端１７Ｂを採血ホ
ルダー１６に装入された採血管１０の栓体１４に
刺通することにより、陰圧状態にある管本体１１
内に血液を採取する。 Specific Effects of the Invention First, the outer end 17A of the blood collection needle 17 is punctured into a patient's vein, and the inner end 17B of the blood collection needle is inserted into the stopper 14 of the blood collection tube 10 inserted into the blood collection holder 16. Due to this, the tube body 11 is in a negative pressure state.
Collect blood inside.
上記採血後、血液と抗凝血剤１２の転倒混和を
行ない、血液の凝固を防止した後、採血管１０を
遠心分離機にかける。この遠心分離により、血液
は、血漿成分１８と凝固が防止された血球成分１
９とに分離され、両成分１８，１９は第３図に示
すように、分離剤１５によつて分画され、相互に
隔絶される。 After the blood collection, the blood and anticoagulant 12 are mixed by inversion to prevent blood from coagulating, and then the blood collection tube 10 is placed in a centrifuge. Through this centrifugation, the blood is separated into a plasma component 18 and a blood cell component 1 that has been prevented from coagulation.
As shown in FIG. 3, both components 18 and 19 are separated by a separating agent 15 and separated from each other.
上記のようにして分離される血漿成分１８は、
分離剤１５によつて血球成分１９と隔絶されてい
ることから、血球成分１９によつて汚染されるこ
となく、正しい凝固系検査用の試料として用いる
ことが可能となる。すなわち、上記分離剤１５に
よつて分離された血漿成分１８は、他の容器に移
しかえられることなく、そのまま、各血液凝固系
検査法に応じて定められている他の試薬を加えら
れ、該血漿成分１８の凝固時間を測定することに
より、被検血液の各種凝血障害の診断を可能とす
る。 The plasma component 18 separated as described above is
Since it is separated from the blood cell component 19 by the separation agent 15, it is not contaminated by the blood cell component 19 and can be used as a correct sample for coagulation system testing. That is, the plasma component 18 separated by the separating agent 15 is directly added with other reagents specified according to each blood coagulation system test method without being transferred to another container. By measuring the coagulation time of the plasma component 18, it is possible to diagnose various coagulation disorders in the test blood.
また、採血管１０は、上記血漿成分１８と血球
成分１９との分離後、そのまゝ試料保存容器とし
て用いることができ、採血管１０の保存、輸送時
にも、血漿成分１８と血球成分１９との混和の可
能性を排除する。また、採血管１０に保存されて
いる試料としての血漿成分１８は、いつでもきわ
めて容易かつ能率的に、デカンテーシヨン、ピペ
ツト等により取り出し可能である。 Further, the blood collection tube 10 can be used as a sample storage container as it is after the plasma component 18 and the blood cell component 19 have been separated, and even when the blood collection tube 10 is stored and transported, the plasma component 18 and the blood cell component 19 are separated. eliminate the possibility of mixing. Furthermore, the plasma component 18 as a sample stored in the blood collection tube 10 can be taken out at any time very easily and efficiently by decantation, pipetting, or the like.
なお、血漿成分１８と血球成分１９とを分離剤
１５によつて分離する状態で保存している採血管
１０を、マイナス20℃のデイープフリーザーで急
速に凍結する実験を、25本の採血管１０について
行なつた結果、ガラス製管本体１１が破損するこ
となく、また、分離剤１５も安定であることが認
められた。 In addition, an experiment was carried out in which blood collection tubes 10, in which plasma components 18 and blood cell components 19 were separated by separation agent 15, were rapidly frozen in a deep freezer at -20°C. As a result, it was found that the glass tube body 11 was not damaged and the separating agent 15 was also stable.
上記実施例によれば、以下の作用効果がある。 According to the above embodiment, there are the following effects.
採血管１０は、抗凝血剤１２の溶液を分離剤１
５の上部に位置させた。 The blood collection tube 10 separates a solution of an anticoagulant 12 into a separating agent 1.
It was located at the top of 5.
すなわち、抗凝血剤１２が液状でありかつ分離
剤１５の上部に位置させたので、採取した血液は
素早く抗凝血剤１２と混合し、さらに遠心分離す
る際に流動性を呈した分離剤１５の動きを妨げる
ものがない。よつて、血漿成分１８と血球成分１
９の境に移動し遠心力の停止に伴い２成分を相互
に隔絶する壁を形成することができる。従つて、
抗凝血剤１２により凝血作用を抑制された血漿成
分１８は血球成分１９と、半固体状の分離剤１５
によつて隔離された状態を維持することができ
る。 That is, since the anticoagulant 12 is in a liquid state and is placed above the separating agent 15, the collected blood quickly mixes with the anticoagulant 12, and when centrifuged, the separating agent exhibits fluidity. There is nothing to hinder the movement of 15. Therefore, plasma component 18 and blood cell component 1
9 and as the centrifugal force stops, a wall can be formed that separates the two components from each other. Therefore,
Plasma component 18 whose coagulation effect has been suppressed by anticoagulant 12 is divided into blood cell component 19 and semi-solid separation agent 15
can maintain an isolated state.
発明の具体的効果
以上のように、本発明に係る血液分離管は、管
体の一部が開口し、他端が閉塞した有底採血管本
体と、該管本体の開口部を密封する穿刺可能な栓
体と、該管本体内に収容され、分離すべき血漿成
分と血球成分の中間比重を有するチキソトロピー
性分離剤と、該管本体の内部であつて該栓体と接
する空間内に血液との接触により血液中に分散可
能に分離剤上部に位置する抗凝血剤溶液とを具備
し、かつ凝固が防止された血液が遠心分離された
後、該血液から血球成分が隔離されるようにした
ものである。したがつて、採取した血液に、凝固
系検査用試薬を混和させるとともに、他の容器に
移しかえることなく、血球成分によつて汚染され
ることのない血漿成分を凝固系検査用試料として
提供可能とし、被検血液の凝血障害を容易にかつ
正確に診断することが可能となる。また、移動さ
せたり、転倒した際にも血漿成分中に血餅や血球
が混入することがない。血漿成分の移しかえが不
要な為、外気に触れることがなく、空気による汚
染が防止されるとともに採血から検査までに要す
る時間が極めて短縮される。さらに遠心分離後、
そのまま試料保存容器として用いることができる
とともに、そのまま他の容器へ移しかえることな
く血糖値を測定することもできる。また、遠心分
離後の血漿成分は分離剤の層により血球成分から
完全に隔離される為、血漿中の繊維素に血球成分
がからみつく恐れがない。したがつて抗凝血剤の
作用では血液の抗凝固化が充分に行なわれなかつ
た場合においても従来のような分離剤を備えない
場合に比し、検査結果を正確なものとすることが
できる。 Specific Effects of the Invention As described above, the blood separation tube according to the present invention includes a bottomed blood collection tube body in which a part of the tube body is open and the other end is closed, and a puncture tube that seals the opening of the tube body. a thixotropic separation agent housed in the tube body and having a specific gravity intermediate between the plasma component and blood cell component to be separated; an anticoagulant solution located above the separating agent so that it can be dispersed into the blood by contact with the blood, and after the blood whose coagulation is prevented is centrifuged, blood cell components are isolated from the blood. This is what I did. Therefore, it is possible to mix collected blood with reagents for coagulation system tests and provide plasma components that are not contaminated by blood cell components as samples for coagulation system tests without having to transfer the blood to another container. This makes it possible to easily and accurately diagnose coagulation disorders in the blood to be tested. Furthermore, even if the device is moved or falls over, blood clots and blood cells will not be mixed into the plasma components. Since there is no need to transfer plasma components, there is no exposure to the outside air, preventing air contamination and extremely shortening the time required from blood collection to testing. After further centrifugation,
It can be used as it is as a sample storage container, and blood sugar levels can also be measured without transferring it to another container. In addition, since the plasma components after centrifugation are completely separated from the blood cell components by the layer of separating agent, there is no fear that the blood cell components will become entangled with fibrin in the plasma. Therefore, even if blood is not sufficiently anticoagulated by the action of anticoagulants, test results can be more accurate than in cases where conventional separation agents are not provided. .
また、本発明は、前記血液分離管内部が所定の
採血量に対応する減圧状態に保持されてなるよう
にしたものである。 Further, in the present invention, the inside of the blood separation tube is maintained at a reduced pressure state corresponding to a predetermined amount of blood to be collected.
第１図は本発明の一実施例に係る採血管を示す
断面図、第２図は同採血管の採血ホルダーへの装
入状態を示す断面図、第３図は同採血管による採
血状態を示す断面図である。
１０……採血管、１１……管本体、１２……抗
凝血剤、１３……口部、１４……栓体、１５……
分離剤、１８……血漿成分、１９……血球成分。
FIG. 1 is a cross-sectional view showing a blood collection tube according to an embodiment of the present invention, FIG. 2 is a cross-sectional view showing the state in which the blood collection tube is inserted into a blood collection holder, and FIG. FIG. 10... Blood collection tube, 11... Tube body, 12... Anticoagulant, 13... Mouth, 14... Stopper, 15...
Separation agent, 18...Plasma component, 19...Blood cell component.
Claims (1)
血管本体と、該管本体の開口部を密封する穿刺可
能な栓体と、該管本体内に収容され、分離すべき
血漿成分と血球成分の中間比重を有するチキソト
ロピー性分離剤と、該管本体の内部であつて該栓
体と接する空間内に血液との接触により血液中に
分散可能に分離剤上部に位置する抗凝血剤溶液と
を具備し、かつ凝固が防止された血液が遠心分離
された後、該血液から血球成分が隔離されること
を特徴とする血液分離管。 ２ 前記血液分離管内部が所定の採血量に対応す
る減圧状態に保持されてなる特許請求の範囲第１
項記載の血液分離管。[Scope of Claims] 1. A bottomed blood collection tube body with one end open and the other end closed, a pierceable stopper that seals the opening of the tube body, and a stopper housed within the tube body. , a thixotropic separating agent having an intermediate specific gravity between the plasma component and the blood cell component to be separated, and an upper part of the separating agent that can be dispersed into the blood by contact with the blood in a space inside the tube body and in contact with the plug body. 1. A blood separation tube comprising: an anticoagulant solution located in the blood separation tube, wherein blood cell components are isolated from the blood after the coagulation-prevented blood is centrifuged. 2. Claim 1, wherein the inside of the blood separation tube is maintained at a reduced pressure state corresponding to a predetermined amount of blood to be collected.
Blood separation tube as described in section.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58061010A JPS59187263A (en) | 1983-04-08 | 1983-04-08 | Blood separation tube |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58061010A JPS59187263A (en) | 1983-04-08 | 1983-04-08 | Blood separation tube |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59187263A JPS59187263A (en) | 1984-10-24 |
| JPH0365497B2 true JPH0365497B2 (en) | 1991-10-14 |
Family
ID=13158931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58061010A Granted JPS59187263A (en) | 1983-04-08 | 1983-04-08 | Blood separation tube |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59187263A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5494590A (en) * | 1992-06-11 | 1996-02-27 | Becton Dickinson | Method of using anticoagulant solution in blood separation |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5737259A (en) * | 1980-08-14 | 1982-03-01 | Sherwood Medical Ind Inc | Covering of stopper for anticoagulation |
| JPS5838536A (en) * | 1981-08-27 | 1983-03-07 | ベクトン・デイツキンソン・アンド・カンパニ− | Blood collecting apparatus |
-
1983
- 1983-04-08 JP JP58061010A patent/JPS59187263A/en active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5737259A (en) * | 1980-08-14 | 1982-03-01 | Sherwood Medical Ind Inc | Covering of stopper for anticoagulation |
| JPS5838536A (en) * | 1981-08-27 | 1983-03-07 | ベクトン・デイツキンソン・アンド・カンパニ− | Blood collecting apparatus |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59187263A (en) | 1984-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2563274C (en) | Specimen collecting, processing and analytical assembly | |
| US5456885A (en) | Fluid collection, separation and dispensing tube | |
| CA2223165C (en) | Apparatus and method for plasma preparation | |
| US3918908A (en) | Method for prothrombin testing | |
| US4104025A (en) | Method of preparing liquid samples for testing | |
| US11622706B2 (en) | Blood sampling device | |
| US3951606A (en) | Apparatus for prothrombin testing | |
| US10730043B2 (en) | Sample collection and separation device | |
| JPH0369069B2 (en) | ||
| US6706536B1 (en) | Method and apparatus for processing coagulation studies, chemistry procedures and the like | |
| JP2007167123A (en) | Vacuum blood collection tube | |
| US4563332A (en) | Liquid sampling apparatus with retention means | |
| US20060216829A1 (en) | Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same | |
| JPH0365497B2 (en) | ||
| JPH0365496B2 (en) | ||
| JP3248501B2 (en) | Blood coagulation tube with blood separation agent | |
| JPS6319556A (en) | Analyzing vessel | |
| Bowen et al. | 4.5 Interferences from Blood Sampling Device Materials on Clinical Assays: I Blood Collection Devices and Their Constituents and Additives | |
| JPS59221666A (en) | Blood separating tube | |
| JPH08292190A (en) | Blood examination container | |
| RU2225002C1 (en) | Method of revealing light-weight fraction of erythrocytes | |
| CA2335409C (en) | Apparatus and method for plasma preparation | |
| Perkins et al. | Evaluation of the Du Pont Axial Separation system | |
| JPH08271505A (en) | Centrifugal separation of blood | |
| JPS5917385B2 (en) | Sealant for serum or plasma separation |